San Diego-based ResMed has completed its $340 million acquisition of Noctrix Health, a medical device company focused on treatments for restless leg syndrome and related sleep disorders. The deal significantly expands ResMed’s portfolio beyond its core respiratory and sleep apnea platforms, positioning the company to address a broader range of sleep-related conditions.
Simultaneously, ResMed announced a partnership with OURA, the company behind the popular OURA Ring wearable, to integrate sleep and health data into actionable clinical insights. The collaboration is designed to connect consumer-grade biometric tracking with ResMed’s clinical-grade respiratory care platforms, potentially enabling earlier detection and intervention for sleep disorders.
The Noctrix acquisition brings a unique therapeutic technology into ResMed’s pipeline. Noctrix developed a wearable device that delivers vibratory therapy to treat restless leg syndrome — a condition that affects an estimated 7–10% of the U.S. population and is frequently comorbid with the sleep apnea conditions ResMed already targets. By combining Noctrix’s therapy with its existing respiratory solutions, ResMed can offer a more comprehensive sleep health platform to both patients and healthcare providers.
The moves reflect an accelerating trend in the San Diego life sciences sector, where established medical device companies are expanding through both acquisition and strategic partnerships. ResMed, headquartered in the Sorrento Valley corridor, has been a pillar of the region’s medtech ecosystem for decades. The Noctrix deal and OURA partnership signal that the company is willing to move beyond its traditional boundaries to capture a larger share of the growing sleep health market.
For San Diego’s broader biotech and medtech economy, the deal reinforces the region’s role as a hub for sleep and respiratory medicine. Multiple companies in the sector — including Illumina spinoffs and startups emerging from Scripps Research — have contributed to a cluster effect that attracts talent and investment to the area. The $340 million acquisition price also signals sustained investor confidence in sleep-focused medtech, a category that has drawn increasing attention since the pandemic elevated public awareness of sleep health and its connection to overall wellness.
